caa a22 4500 477036791 CHVBK 20180405111307.0 cr unu---uuuuu 170330e19960201xx s 000 0 eng 10.1007/s002689900031 doi (NATIONALLICENCE)springer-10.1007/s002689900031 Arnold R. Department of Internal Medicine, Division of Gastroenterology and Metabolism, Philipps-University Marburg, Baldingerstrasse, D-35033 Marburg, Germany, DE aut Medical Treatment of Metastasizing Carcinoid Tumors [Elektronische Daten] [R. Arnold] Abstract. Long-acting somatostatin analogs, such as octreotide, comprise the therapeutic modality of choice for the symptomatic relief of flush and diarrhea in patients with carcinoid syndrome. The sequelae of gastric acid hypersecretion in patients with gastrin-producing duodenal carcinoids (gastrinoma) are perfectly controlled by proton pump inhibitors. Antiproliferative medical strategies to control the growth of metastatic carcinoid tumors include long-acting somatostatin analogs, interferon alpha, and the combination of the two. However, the success rate is less than 50%, and it is questionable whether true tumor regression can be expected. Controlled prospective studies are mandatory to address the question whether interferon or somatostatin analogs or the combination of the two should be used as first-line medical strategies and if hepatic artery embolization in patients with liver metastases should be performed before beginning medical therapy. Chemotherapy, including etoposide and cisplatin, has been shown to be effective only for purely differentiated neuroendocrine carcinomas and not for slowly growing carcinoids.: 1996 by the Société Internationale de Chir, ugie https://doi.org/10.1007/s002689900031 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002689900031 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Arnold R. Department of Internal Medicine, Division of Gastroenterology and Metabolism, Philipps-University Marburg, Baldingerstrasse, D-35033 Marburg, Germany, DE aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer